- Home
- DRCT vs HCWB Comparison
DRCT vs HCWB Comparison
Compare DRCT & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- HCWB
- Stock Information
- Founded
- DRCT 2018
- HCWB 2018
- Country
- DRCT United States
- HCWB United States
- Employees
- DRCT N/A
- HCWB N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- HCWB Biotechnology: Pharmaceutical Preparations
- Sector
- DRCT Technology
- HCWB Health Care
- Exchange
- DRCT Nasdaq
- HCWB Nasdaq
- Market Cap
- DRCT 8.8M
- HCWB 8.4M
- IPO Year
- DRCT 2022
- HCWB 2021
- Fundamental
- Price
- DRCT $0.38
- HCWB $3.91
- Analyst Decision
- DRCT Strong Buy
- HCWB Strong Buy
- Analyst Count
- DRCT 1
- HCWB 1
- Target Price
- DRCT $6.00
- HCWB $35.00
- AVG Volume (30 Days)
- DRCT 5.4M
- HCWB 95.1K
- Earning Date
- DRCT 11-06-2025
- HCWB 11-13-2025
- Dividend Yield
- DRCT N/A
- HCWB N/A
- EPS Growth
- DRCT N/A
- HCWB N/A
- EPS
- DRCT N/A
- HCWB N/A
- Revenue
- DRCT $36,459,000.00
- HCWB $832,841.00
- Revenue This Year
- DRCT $16.81
- HCWB $178.64
- Revenue Next Year
- DRCT $35.28
- HCWB N/A
- P/E Ratio
- DRCT N/A
- HCWB N/A
- Revenue Growth
- DRCT N/A
- HCWB N/A
- 52 Week Low
- DRCT $0.28
- HCWB $2.77
- 52 Week High
- DRCT $6.59
- HCWB $100.80
- Technical
- Relative Strength Index (RSI)
- DRCT 53.54
- HCWB 46.08
- Support Level
- DRCT $0.35
- HCWB $4.00
- Resistance Level
- DRCT $0.37
- HCWB $3.92
- Average True Range (ATR)
- DRCT 0.03
- HCWB 0.17
- MACD
- DRCT 0.01
- HCWB -0.02
- Stochastic Oscillator
- DRCT 66.89
- HCWB 8.57
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.